Abstract: Disclosed are apo-, holo-, and acylated-acyl carrier proteins modified to have a non-radioactive label covalently bonded to a modified tyrosine residue within the acyl carrier protein. Also disclosed are methods of using the labeled acyl carrier proteins to investigate reaction involving or mediated by acyl carrier proteins. Also disclosed are kits containing the non-radioactively-labeled acyl carrier proteins.

Abstract: The present invention relates to polynucleotide and polypeptide molecules for Zcyto21, an interferon-like protein, which is most closely related to interferon-? at the amino acid sequence level. The present invention also includes antibodies to the Zcyto21 polypeptides, and methods of using the polynucleotides and polypeptides.

Abstract: The present invention relates to polynucleotide and polypeptide molecules for Zcyto21, an interferon-like protein, which is most closely related to interferon-? at the amino acid sequence level. The present invention also includes antibodies to the Zcyto21 polypeptides, and methods of using the polynucleotides and polypeptides.

Abstract: Transglutaminase polypeptides, polynucleotides encoding them, methods of making them, and methods of using them are disclosed. The polypeptides comprise residues 1-X of SEQ ID NO:2, wherein X is an integer from 462 to 704, inclusive. The compositions and methods of the invention may be used for a variety of purposes in industry, research, and medicine.

Abstract: Compounds, pharmaceutical compositions and methods that are useful in the treatment or prevention of metabolic and cell proliferative diseases or conditions are provided herein. In particular, the invention provides compounds which modulate the activity of proteins involved in lipid metabolism and cell proliferation.

Abstract: The I/O circuit of the present invention provides optimal flexibility and performance using a number of different structures and methods. The present invention provides a signal follower circuit for an input pad. In one embodiment, the output buffer is capable of injecting a constant onto a pad during reconfiguration of a configurable system logic circuit. The present invention also provides a circuit for generating a programmable data propagation delay, thereby guaranteeing zero hold time for an arbitrary input register. Zero hold time is accomplished by allowing the user to optimally characterize clock delay to a given input/output circuit. The present invention also provides fast switching between input pads, thereby minimizing data propagation delay between the input pads. Additionally, the present invention reduces time spent in production product test by facilitating the testing of multiple routes with one test configuration.

Abstract: Novel zacrp11 polypeptides, polynucleotides encoding the polypeptides, and related compositions and methods are disclosed. Also disclosed are antibodies to the zacrp11 protein and fragments thereof.

Abstract: A method and apparatus for providing a system-on-a-chip comprising a processor and a configurable system logic (CSL) including a plurality of banks arranged in an array coupled to the processor. The system on a chip further includes a built-in self test (BIST) mechanism coupled to the CSL to perform tests on the CSL to verify that the banks and interconnections between the banks are functioning properly.

Abstract: Novel zacrp12 polypeptides, polynucleotides encoding the polypeptides, and related compositions and methods are disclosed. Also disclosed are antibodies to the zacrp12 protein or fragments thereof.

Abstract: The present invention allows a user to customize the configuration sequence of a configurable system on a chip (CSoC), thereby adding considerable flexibility to the configuration process. The present invention also provides certain features, transparent to the user, which optimize system resources and ensure the correct initialization of the CSoC. The CSoC leverages an on-chip central processing unit (CPU) to control the configuration process of the configurable system logic (CSL). Advantageously, the CSL configuration memory cells as well as other programmable locations in the CSoC are addressable as part of a system bus address space. The system bus is a multi-use structure that can be used for both configuring and reading of memory cells. In this manner, the CSoC optimizes system resources.

Abstract: The present invention relates to polynucleotide and polypeptide molecules for Zcyto21, an interferon-like protein, which is most closely related to interferon-? at the amino acid sequence level. The present invention also includes antibodies to the Zcyto21 polypeptides, and methods of using the polynucleotides and polypeptides.

Abstract: A soluble receptor to IL-20 having two polypeptide subunits, IL-20RA (formerly called ZcytoR7) and IL-20RB (formerly called DIRS1). The two subunits are preferably linked together. In one embodiment one subunit is fused to the constant region of the light chain of an immunoglobulin, and the other subunit is fused to the constant region of the heavy chain of the immunoglobulin. The light chain and the heavy chain are connected via a disulfide bond.

Abstract: Systems and methods are defined for facilitating the audit process involving a business client, an auditor, and a third-party providing confirmations for the client upon the auditor's request. More specifically, an auditor receives an audit number from the audited client as evidence of authorization for requesting confirmation from a third-party, such as a bank or related business entity. The confirmation request submitted by the auditor will be stored in a network-based computer system and transmitted to the relevant third-party. The third-party then provides necessary confirmation data in response to the request and has the confirmation data transferred to the auditor through the computer system over the Internet. The involved third-party can be a bank or financial institution, another entity in business relationship with the client, or any other entity that has access to the requested data associated with the client.

Abstract: The present invention relates to polynucleotide and polypeptide molecules for Zcyto21, an interferon-like protein, which is most closely related to interferon-&agr; at the amino acid sequence level. The present invention also includes antibodies to the Zcyto21 polypeptides, and methods of using the polynucleotides and polypeptides.

Abstract: Interface logic is disclosed. The interface logic comprises a first address decoder, a first set of mode logic coupled to the address decoder and a first selector coupled to the first set of mode logic. The interface logic is adaptable to connect the programmable logic to the system interconnect via one of a plurality of access modes supported by the system interconnect.

Abstract: The present invention relates to polynucleotide and polypeptide molecules for zacrp13, a novel member of the family of proteins bearing a collagen-like domain and a C1q domain. Novel zacrp13 polypeptides, polynucleotides encoding the polypeptides, and related compositions and methods are disclosed. Also disclosed are antibodies to the zacrp13 protein or fragments thereof.

Abstract: Novel zacrp8 polypeptides, polynucleotides encoding the polypeptides, and related compositions and methods of using are disclosed. Also disclosed are antibodies to the zacrp8 protein or fragments thereof.

Abstract: Novel zacrp14 polypeptides, polynucleotides encoding the polypeptides, and related compositions and methods are disclosed. Also disclosed are antibodies to the zacrp14 protein or fragments thereof.

Abstract: The present invention relates to polynucleotide and polypeptide molecules for zacrp13, a novel member of the family of proteins bearing a collagen-like domain and a C1q domain. Novel zacrp13 polypeptides, polynucleotides encoding the polypeptides, and related compositions and methods are disclosed. Also disclosed are antibodies to the zacrp13 protein or fragments thereof.

Abstract: Proteins consisting of, from amino to carboxyl terminus, a first PDGF-D growth factor domain polypeptide, a linker polypeptide, and a second PDGF-D growth factor domain polypeptide, and materials and methods for making the proteins are disclosed. Each of the first and second PDGF-D growth factor domain polypeptides consists of a sequence of amino acid residues as shown in SEQ ID NO: 2 or SEQ ID NO: 4 from amino acid x to amino acid y, wherein x is an integer from 246 to 258, inclusive, and y is an integer from 365-370, inclusive. The linker polypeptide consists of from 11-40 amino acid residues. The proteins can be used to stimulate the production of bone and/or connective tissue in both humans and non-human animals.